2 No-Brainer Vanguard ETFs to Buy During the Stock Market Sell-Off

The S&P 500 is roughly 9% below its January record high, approaching correction territory, while Vanguard Growth ETF (VUG) is down ~16% from its peak. Middle East geopolitical tensions have pushed oil prices higher, creating inflationary and potential interest-rate risks, but the piece recommends using broad (VOO, 0.03% ER) or concentrated growth (VUG, ~64% tech; top weights: NVDA 12.82%, AAPL 12.23%) ETFs as long-term buying opportunities. Historical context: S&P 500 has delivered a 10.6% CAGR since 1957 and an accelerated ~21.7% annualized return since the AI rally began in early 2023, though higher-growth ETFs have shown greater volatility (VUG +297% vs S&P +209% over the last decade).

Analysis

The market’s concentration in a handful of AI/mega-cap names creates a two-way lever: positive flows into growth ETFs amplify rallies, but the same concentration magnifies drawdowns and creates liquidity risk around earnings or guidance shocks. When passive flows reverse or options dealers hedge, we should expect outsized intra-day and multi-day moves in NVDA, AVGO, AAPL and MSFT versus the broad market — not because fundamentals change immediately but because positioning and gamma dynamics do.

Second-order winners are firms supplying high-margin AI systems (chip designers, interconnect and software ISVs) that can expand realized ASPs as buyers prioritize time-to-market; AVGO is the archetype in our universe. Losers over the medium term include incumbents with heavy capital and process-transition costs (INTC) and consumer-exposed cyclicals that face input-cost pressure if energy-driven transport inflation persists, which would compress discretionary margins before any Fed reaction materializes.

Key tail risks are geopolitical escalation that sustains oil spikes (3–6 month lag into core services CPI), a faster-than-expected Fed tightening path that re-rates long-duration growth multiples within 2–4 quarters, and an AI demand normalization if hyperscalers pause incremental capex after inventory digestion over the next 2 earnings cycles. Watch options skew and ETF inflows as high-frequency early-warning signals: widening skews + outflows precede multi-week unwind events.

Contrarian angle: the market’s “buy the leaders” reflex is underpricing the probability of a concentrated, liquidity-driven drawdown rather than a fundamental growth failure. Position for asymmetric outcomes with defined-risk longs in secular winners and relative shorts of structurally challenged players rather than naked market shorts.

Key Decisions for Investors

• AVGO/INTC pair (relative-value): Go long AVGO equity (6–12 month horizon) and short INTC equal notional. Thesis: AVGO captures AI ASP leverage while INTC continues to face process-cycle capex drag. Target relative outperformance 25–40%; cut position if pair moves 10% adverse intraday or after a material catalyst (earnings/process guidance).
• NVDA defined-risk calls (directional): Buy a 3–6 month call spread on NVDA sized for a max loss of 2% portfolio exposure. Rationale: capture near-term AI revenue cadence with capped downside; target payoff 2:1–3:1 if guidance stays intact. Monitor options skew; exit or roll early if implied vol jumps >40% vs historical.
• Core equity + convex hedge (SPX/VOO): Maintain a core long in broad market exposure and buy 3-month 5% OTM put spreads sized to cap drawdown to ~3–4% portfolio risk. This preserves upside capture while limiting tail risk from a geopolitically driven oil/inflation shock over the next 1–3 months.
• Defensive healthcare long (JNJ or ABBV): Add a 9–18 month overweight in JNJ/ABBV via equity or deep ITM call/LEAP to lower portfolio beta and collect yield while volatility is elevated. Target total return 15–25% with lower sensitivity to rate-driven multiple compression; trim into any >20% rally.